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Hepatitis C virus (HCV) induces a chronic infection in more than two-thirds of HCV infected subjects. The inefficient
innate and adaptive immune responses have been shown to play a major pathogenetic role in the development
and persistence of HCV chronic infection. Several aspects of the interactions between the virus and the host
immune system have been clarified and, in particular, mechanisms have been identified which underlie the ability
of HCV to seize and subvert innate as well as adaptive immune responses. The present review summarizes recent
findings on the interaction between HCV infection and innate immune response whose final effect is the
downstream inefficient development of antigen-specific adaptive immunity, thereby contributing to virus
persistence.
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Systems biologyHepatitis C virus: a brief overview
Hepatitis C virus (HCV) is a Hepacivirus of the Flaviviridae
family, mainly involved in hepatic disorders, including
chronic hepatitis which may progress to cirrhosis in about
10–20% of cases and further to hepatocellular carcinoma
(HCC) in 1–5% of cirrhotic patients [1]. Furthermore,
HCV has also been implicated as one of the major etio-
logic factors for type II Mixed Cryoglobulinemia (MC), an
autoimmune disease that may evolve into an overt B-cell
non-Hodgkin’s lymphoma (NHL) in about 10% of MC
patients [2-4].
HCV is an enveloped positive-strand RNA virus. Six
major HCV genotypes and more than 100 subtypes have
been so far identified [5-7]. HCV genomic RNA contains
a single open reading frame flanked by 50 and 30 untrans-
lated regions (UTRs) [8,9], which encodes for a single
large polyprotein, processed by cellular and viral pro-
teases to produce structural as well as non structural
proteins [9,10].
The core (C) and envelope proteins (E1 and E2) are
structural components of the infectious particle [11],
whereas the non structural (NS) proteins are required
for RNA replication (NS3–NS5B), particle assembly* Correspondence: irccsvir@unina.it
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distribution, and reproduction in any medium(p7 and NS2) and protein maturation (NS2 and NS3/4A
complex) [10,12].
HCV entry into hepatocytes is mediated by one of the
following putative receptors, such as the CD81 tetraspa-
nin [13], the scavenger receptor class B type I [14], the
tight junction proteins claudin [15,16] and occludin [17],
the latters conferring species specificity.Innate immune response to HCV
As for all microbial infections, innate immune response
plays a critical role in the control and resolution of HCV
infection providing signals for the efficient priming of
the adaptive branch of immune response [18,19].
In particular, the innate immunity is important in
HCV infection to control viral dissemination and repli-
cation in order to allow an adequate downstream devel-
opment of antigen-specific humoral as well as cellular
responses [20].
During the early phase of HCV infection, the viral
RNA load increases in the first few days and remains
high throughout the incubation period, which lasts for
up to 10–12 weeks post-infection [21,22]. In such early
stage, large amounts of type I interferons (IFN-α, IFN-β)
may be produced by HCV-infected hepatocytes as well
as dendritic cells (DCs) to control viral replication [23].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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compartment of innate immunity, orchestrating the qual-
ity and potency of downstream adaptive immune re-
sponse. They are professional antigen presenting cells
(APCs) able to uptake and process viral antigens, as well
as release cytokines to efficiently prime both CD4+ helper
T cells and CD8+ cytotoxic T lymphocytes (CTLs) [24].
In particular, the subset of plasmacytoid DCs (pDCs) is
considered the front line in antiviral immunity owing to
their capacity to rapidly produce high amounts of type I
interferon in response to viruses, upon recognition of viral
components and nucleic acids through Toll-like receptor
(TLR) 7 and TLR9 [25,26]. To further support such role,
several reports show a decreased frequency of pDCs in
peripheral blood of patients with chronic HCV infection
and impaired production of IFN-α by pDCs from HCV
patients [27-29]. Also, myeloid or conventional DCs
(cDCs) are programmed to produce IFN-α in response to
viral infection upon interaction between viral double-
stranded RNA-like molecule polyinosinic:polycytidylic
acid (poly I:C) and TLR3 [30]. Moreover, cDCs produce
high amounts of cytokines, such as IL-12, which has been
shown to play an important role in stimulating IFN-γ pro-
duction from activated T cells, inducing the development
of type 1 (Th1) protective immune response [31,32]. In-
deed, a recent study showed that an increased number of
cDCs during acute HCV infection may be associated with
viral clearance, whereas a loss in the number of cDCs may
increase the risk for development of chronic HCV infec-
tion [33,34].
Also natural killer (NK) cells are potent antiviral
effectors due to their contribution to virus elimination
via direct killing of infected cells and cytokine produc-
tion [35]. Genetic factors appear to contribute to the
level of NK cell responsiveness, as shown by the pres-
ence of individual killer cell Ig-like receptor/human
leukocyte antigen (KIR/HLA) compound genotypes cor-
related with HCV clearance [36]. In particular, given that
the interaction between KIRs expressed on NK cells and
HLA expressed on target cells plays a key role in NK cell
activation, it has been suggested that such genotypes are
characterized by a higher sensitivity of NK cells with a fas-
ter degranulation and IFN-γ release in vitro [37].
Nevertheless, innate immune response to HCV may
also be detrimental inducing immunopathological effects
on the liver. NK-mediated killing of HCV-infected hepa-
tocytes and secretion of proinflammatory cytokines may
cause liver damage, stimulating cDCs to produce high
amount of IFN- γ which, subsequently, activates hepatic
macrophages to enhance local inflammation [38]. All
such cascade of events contributes to the pathogenesis
of liver disease [39].
The overall data demonstrate the complex, contradict-
ory and evolving equilibrium between HCV and hostinnate immunity, whose result will lead to completely
different clinical outcomes ranging from resolution to
chronic viral infection.
Pattern recognition receptors in sensing virus
infection
The innate immune response to virus infection is acti-
vated when conserved motifs of microbial origin, known as
pathogen-associated molecular patterns (PAMPs) are recog-
nized by cell pattern recognition receptors (PRRs) [40].
The 3 major classes of PRRs include Toll-like receptors
(TLRs), RIG-I-like receptors (RLRs), and nucleotide
oligomerization domain (NOD)-like receptors (NLRs)
[41-43]. Viral engagement of TLRs and RLRs leads to the
activation of transcription factors, such as the IFN regu-
latory factors (IRFs) and NF-κB, which in turn may lead
to the activation of IRF3 target genes, type I IFN, and
proinflammatory cytokines [44].
So far, the role of NLRs in sensing RNA viruses is still
unclear and they are primarily thought to be activated by
intracellular stress signals (i.e. damage-associated molecu-
lar patterns, DAMPs) [45]. In this regards, DAMPS derived
from HCV infected hepatocytes may play a critical role in
promoting liver inflammation with immunopathological
effects.
Innate immune cells (i.e. monocytes, neutrophils, den-
dritic cells) are rapidly activated upon recognition of
infecting agents by a wide range of PRRs. Among them,
the Toll-like receptors are members of the interleukin-1
receptor (IL-1R) superfamily [46,47], characterized by a
leucine-rich repeat (LRR) domain in the extracellular re-
gion and an extracellular Toll/IL-1R (TIR) domain [48].
So far, 11 TLRs have been identified. TLR1, TLR2,
TLR6 and TLR10 are closely related to the TLR2 subfam-
ily, whereas, TLR7, TLR8 and TLR9 are closely related to
the TLR9 subfamily [49]. Each TLR has specific ligands,
which allow the host to sense a wide diversity of patho-
gens [50]. As a result of TLR stimulation, proinflamma-
tory cytokines are released that activate the host immune
response [51-53].
Most TLRs (except for TLR3) share a common signal-
ling pathway, via the adaptor molecule, myeloid differenti-
ation primary response protein 88 (MyD88) [54-56]. TLRs
recruit MyD88 via TIR domains, then MyD88 binds the
IL-1R-associated kinase (IRAK) and the signal is propa-
gated to tumor necrosis factor (TNF) receptor-associated
factor-6 (TRAF6), for activation of NF-kB and mitogen-
activated protein kinases (MAPK). A second pathway
involves the TIR-associated protein (TIRAP)/MyD88-
adaptor-like (Mal) for TLR1/2, TLR2/6 and TLR4 signal-
ling [57,58].
On the contrary, TLR3 signalling is independent of
MyD88 and is mediated by TIR-domain containing
adaptor inducing IFN-b (TRIF)_toll-like receptor adaptor
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regulatory factor-3 (IRF-3) transcription factor and subse-
quent production of IFN-β [59].
The RIG-I-like receptors (RLRs) are sensors of viral
RNA, consisting of three members: RIG-I, melanoma dif-
ferentiation antigen 5 (MDA5) [60] and laboratory of genet-
ics and physiology-2 (LGP2) [61-64]. RLRs are expressed in
the cytoplasm of most cells, including hepatocytes, repre-
senting good candidates as primary intracellular sensors
of HCV infection. Both RIG-I and MDA5 contain 2
N-terminal caspase activation and recruitment domains
(CARD) [65]. Moreover, all the RLRs have a DExD/H RNA
helicase domain and bind to RNA ligands [66]. In addition,
RIG-I has a repressor domain that interacts with the CARD
domains to maintain the receptor in a non-active conform-
ation in the absence of infection [67]. LGP2 lacks the
CARD domains and may function as a regulator of RLR
signalling [68]. RIG-I senses non-self double-stranded
RNAs (dsRNAs) with free 50-triphosphates and is recruited
to the mitochondrial surface, where interacts with MAVS
(mitochondrial antiviral signalling protein; also known as
IFN-β promoter simulator 1 (IPS-1), virus-induced signal-
ing adapter (VISA), and CARD adaptor inducing IFN-β
(Cardif)) on the outer mitochondrial membrane. MAVS is
a CARD protein and an essential adaptor for RLR signalling
[69]. The interaction between RIG-I and MAVS results in
the activation of the transcription factors, interferon regula-
tory factor-3 (IRF-3) and nuclear factor-kB (NF-kB) with
subsequent transcription of IFN-β [70].Figure 1 Modulation of innate immune response by HCV. Effects of di
immune anti-viral activity are schematically represented.Overall, the data show that, regardless the class of
PRRs engaged upon viral recognition, the activated path-
ways in cells of the innate immunity converge to induce
the production of type I IFN with highly effective anti-
viral activity.
IFN signalling during HCV infection
The production of IFN-β resulting from HCV infection
leads to activation of the JAK (Janus kinase)/STAT (signal
transducer and activator of transcription) signalling path-
way with the expression of interferon-stimulated genes
(ISGs) (Figure 1) [71,72].
Among others, an increased expression has been
described for the 20-50-oligoadenylate synthase 1 (OAS1)/
RNAse L system, which degrades viral and cellular RNA
[73], and the RNA-specific adenosine deaminase acting
on RNA 1 (ADAR1), which converts adenosine residues
into inosine residues in dsRNA [74], thereby mutating
and destabilizing secondary viral RNA structures [75].
Similarly, induction of other ISGs, such as P56 [76] and
protein kinase R (PKR) [77], which inhibit translation of
viral and host RNAs [78], has been reported. Such induc-
tion of ISGs will ultimately amplify the IFN response, in
a loop fashion, given that some pattern recognition and
signalling molecules are ISGs per se, such as RIG-I, TLR3
and TRIF, whose final outcome is the production of IFN-β
(Figure 1) [79].
In this complex framework, HCV establishes a chronic
persisting infection when is able to disrupt the hostfferent HCV factors, RNA or proteins, on cellular mediators of innate
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major strategy employed by HCV to subvert the host in-
nate immune response is to undermine IFN antiviral ac-
tivity [80] as well as functions of innate immune cells.
Regarding the IFN activity, the main targets of HCV are
represented by the PAMP signalling pathways leading to
IRF-3 activation, the IFN-α/β receptor signalling pathway
and the ISG effector proteins (Figure 1). In particular,
HCV NS3/4A protein cleaves the adaptor molecules TRIF
and IPS-1, thereby blocking TLR3 and RIG-I signalling
pathways [81]. Moreover, the HCV core protein interferes
with JAK/STAT signalling and ISGs expression by several
strategies, including 1) inhibition and degradation of
STAT1 [82]; 2) induction of the suppressor of cytokine
signaling 3 (SOCS3) and protein phosphatase 2A (PP2A),
which are an inhibitor of the JAK/STAT pathway [83] and
a reducer of the transcriptional activity of ISG factor 3
(ISGF3) [84], respectively; 3) inhibition of ISGF3 binding
to IFN-stimulated response elements (ISRE).
Furthermore, several HCV proteins directly interfere
with the function of ISGs. Indeed, functional genomics
analyses have shown that the NS5A protein induces a
general attenuation of ISG expression via an increased
secretion of IL-8 [85] and a subsequent modulation of
IFN functions. In support of such inhibitory mechanism,
serum levels of IL-8 have been found elevated in patients
with chronic hepatitis C. In addition, NS5A inhibits 20-50
oligoadenylate synthetase (20-50 OAS) and PKR function
[86] and E2 acts as decoy target to PKR [87].
Even though such escape strategies still need to be
validated in vivo, the available data strongly suggest that
HCV has established redundant means to cope with the
host IFN response.Interactions between HCV and cellular
compartments of innate immunity
More recently, several reports have suggested that HCV
itself may actively suppress the host immune response
by inhibiting the function of innate immune cells.NK cells
NK cell activation, during the early phase of HCV infec-
tion, is involved in viral eradication, whereas direct sup-
pression of NK cells may be implicated in HCV chronic
persistence [88]. It has been reported that the binding of
HCV E2 protein to the CD81 receptor on NK cells inhi-
bits their function and IFN-γ production [89,90]. Such
results, however, are still controversial and their biological
significance in vivo needs to be verified, considering that
HCV E2 does not efficiently crosslink CD81 on NK cells
when it is part of infectious virions, and NK cell function
is not impaired after in vitro exposure to high concentra-
tions of cell culture–produced HCV [91].The HCV core protein induces an up-regulation in the
expression of major histocompatibility complex (MHC)
class I molecules on the surface of hepatocytes by increas-
ing the expression of transporter associated with antigen
processing 1 (TAP1). The resulting suppression of NK cells
activation and cytotoxic activity significantly contribute to
HCV persistence [92].
In addition, it has been reported that NK cells from
chronic HCV-infected individuals show an increased ex-
pression of CD94/NKG2A inhibitory receptor, as well as
production of immunosuppressive IL-10 and TGFβ. The
sum of these effects is the functional impairment of NK
cells to activate DCs and, ultimately, to generate Th1
CD4+ T cells [93].DC cells
DC response to HCV in the early stage of infection is
crucial in determining the outcome of the disease and
several studies indicate that chronic HCV-infected indi-
viduals show an impaired function of DC subsets.
The frequency of circulating pDCs [94], as well as their
ability to produce IFN-α upon in vitro stimulation [95] are
reduced in chronic HCV patients and different mechanisms
have been proposed. HCV core and NS3 proteins have been
shown to activate in vitro monocytes via TLR2 to produce
TNF-α, which in turn inhibits IFN-α production and
induces pDCs apoptosis [96]. Alternatively, HCV may dir-
ectly inhibit IFN-α production by pDCs in vitro [97].
Similarly, maturation and functional differentiation of
cDCs are altered in HCV infection, with decreased IL-12
and increased IL-10 production in vitro [98,99], possibly
resulting in insufficient T cell priming and delayed HCV-
specific T cell responses. However, the impaired allostimu-
latory capacity of cDCs in chronic HCV patients is still
contradictory, being described in some [100-102] but not
all studies [103].
For both subsets of DCs, indeed, functional defects have
been observed in vitro upon stimulation with individual
HCV proteins but do not reflect an immune com-
promised status in chronic HCV patients, who show nor-
mal responsiveness to other viruses or recall antigens
(reviewed in [104,105]). Therefore, the impaired efficacy
of DCs compartment (i.e. pDCs) in chronic HCV patients
would not be due to a “primary” dysfunction of such cells
in producing type I IFNs but, more likely, to a “secondary”
non-responsiveness of target HCV-infected hepatocytes,
given the capacity of HCV to inhibit the IFN-stimulated
signal pathway.
Overall data suggest that HCV interacts with and affects
the function of different actors of the innate immunity.
HCV interference is diverse with regard to cellular levels,
targets and outcomes, however, the overall disruption of
the coordinated activity of the innate immune response
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tion of pathogen elimination (Figure 2).
HCV disease: a microarray’s view
The interplay between HCV and innate immunity can
nowadays be addressed and studied by systems biology
approaches which provide detailed level of investigation to
better and fully analyze the network of interactions within
virus and innate immunity. Conversely to traditional “re-
ductionist” approach, indeed, the paradigm of systems biol-
ogy is to look at a biological system as a whole, evaluating
interactions among biological elements and their relation-
ship with the surrounding environment. Systems biology
has been increasingly applied to oncology [106-108], auto-
immunity and infections [109,110] and only recently to
vaccinology [111-113].
Microarray analyses of gene transcriptional profiles
have been performed to identify molecular signatures of
the innate immunity compartment related to HCV infec-
tion (Table 1).
It has been recently shown that specific immune genes
are significantly increased in HCV cirrhotic liver as com-
pared to control normal tissue [114]. Such genes include
IRF1, tripartite motif-containing 22 (TRIM22), and mul-
tiple leukocyte immunoglobulin-like receptors (LILRA1,
LILRA4, LILRA5, LILRB2, LILRB3 and LILRB4), which
have been reported to play a role in the virus – host
interaction.
IRF1 is a critical transcriptional regulatory factor that
modulates ISG expression and has been shown to regulateFigure 2 Interactions between HCV and target cells. Effects of the HCV
been described. Inhibitory strategies (confirmed and contradictory) employHCV subgenomic replicon activity in cultured hepatoma
cells [115]. Interestingly, polymorphisms in the IRF1 pro-
moter have been associated with a better response to IFN-α
therapy in patients with chronic HCV infection [116].
TRIM22 belongs to the tripartite motif family of pro-
teins which have been associated with innate immune re-
sponse to viruses, inhibiting viral replication [117].
Moreover, multiple leukocyte immunoglobulin like
receptors (LILRs) are known to be expressed on myelo-
monocytic cells and can influence both the innate and
acquired immune response. In particular, LILRB2 has been
previously reported to be up-regulated also in HIV patients
and may impair the antigen presentation function of
monocytes [118], whereas, LILRB4 has been shown to
impair antigen presentation and T cell recruitment modu-
lating the expression of proinflammatory cytokines [119].
A different study showed a total of 524 genes differen-
tially expressed in “advanced HCV” as compared to non
viral hepatitis, with 466 up-regulated genes and 58
down-regulated genes [120]. The most affected bio-
logical functions observed in “advanced HCV” include
the canonical pathways of calcium signalling, hepatic
fibrosis/stellate cell activation and actin cytoskeleton sig-
nalling. Moreover, many differentially expressed genes
involved in the pathways of immune system, fibrosis,
proliferation, cell growth, and apoptosis have been found
to be up-regulated according to previously published
data [121-123]. The majority of such genes are involved
in the pathway of the immune and inflammatory re-
sponse, including: class II major histocompatibilityinfection on hepatocytes as well as cells of the innate immunity have
ed by individual HCV proteins have been indicated.
Table 1 Differentially expressed genes identified in listed studies on liver tissues from chronic HCV patients
GENE NAME DESCRIPTION
Folkers et al. [114]
IFNAR1 Interferon-alpha/beta receptor alpha chain Precursor
IRF1 Interferon regulatory factor 1
LAIR1 Leukocyte-associated immunoglobulin-like receptor 1 Precursor
LEAP2 Liver-expressed antimicrobial peptide 2 Precursor
LILRA1 Leukocyte immunoglobulin-like receptor subfamily A member 1 Precursor
LILRA4 Leukocyte immunoglobulin-like receptor subfamily A member 4 Precursor
LILRA5 Leukocyte immunoglobulin-like receptor subfamily A member 5 Precursor
LILRB2 Leukocyte immunoglobulin-like receptor subfamily B member 2 Precursor
LILRB3 Leukocyte immunoglobulin-like receptor subfamily B member 3 Precursor
LILRB4 Leukocyte immunoglobulin-like receptor subfamily B member 4 Precursor
MAP4K2 Mitogen-activated protein kinase 2
PSMB4 Proteasome subunit beta type-4 Precursor
RFX5 DNA-binding protein RFX5
TRIM22 Tripartite motif-containing protein 22
TRIM34 Tripartite motif-containing protein 34
Khalid et al. [138]
CCR4 Chemokine receptor 4
CXCL10 Chemokine ligand 10
HLA DQβ1 Major histocompatibility complex II DQ beta1
HLA DQχ1 Major histocompatibility complex II DQ alpha1
IFI16 IFNα induced protein 16
IGLL Immunoglobulin lambda locus
IL2RA Interleukin 2 receptor alpha
LGALS3 Lectine galactoside binding soluble 3
SCYA19 Small inducible cytokine subfamily A
SGK Serum/glucocorticoid regulated kinase
Blackham et al. [139]
CXCL1 Chemokine ligand 1
CXCL16 Chemokine ligand 16
CXCL2 Chemokine ligand 2
CXCL3 Chemokine ligand 3
CXCL5 Chemokine ligand 5
CXCL6 Chemokine ligand 6
IL-8 Interleukin 8
IRF1 Interferon regulatory factor 1
IRF9 Interferon regulatory factor 9
MASP1 Mannan-binding lectin serine protease 1
MBL2 Mannose-binding lectin (protein C) 2, soluble
MX1 Interferon-induced GTP-binding protein Mx1
SOCS2 Suppressor of cytokine signaling 2
SOCS3 Suppressor of cytokine signaling 3
De Giorgi et al. [128]
B2M Beta 2 microglobulin
CD7 CD7 molecule
HLAF Major histocompatibility complex, class I, F
IFI16 IFNα induced protein 16
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Table 1 Differentially expressed genes identified in listed studies on liver tissues from chronic HCV patients (Continued)
IFI27 IFNα induced protein 27
OASL 20-50-oligoadenylate synthetase-like protein
PSMB9 Proteasome subunit beta type-9
PSME2 Proteasome activator subunit 2
STAT Signal transducer and activator of transcription 1, 91 kDa
TAP1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)
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mokine receptors [124].
Moreover, a microarray analysis performed on Huh7
hepatocarcinoma cell line demonstrated that infection
with HCV JFH-1 viral particles alters the expression of
host genes involved in cellular defense mechanisms that
protect the cell against infection and oxidative stress
which, in turn, determine the fate of cellular survival
[125]. Furthermore, HCV JFH-1 infection is able to stimu-
late the expression of proinflammatory antiviral response
genes, including those involved in type I and II interferon
responses (e.g. IRF1, IRF9, and myxovirus (influenza virus)
resistance 1, interferon-inducible protein p78 (mouse)
(MX1) genes), the complement cascade (e.g. mannose-
binding lectin (MBL) 2 and mannose-binding protein
associated serine protease (MASP) 1 genes), and the pro-
duction of proinflammatory chemokines and cytokines
(e.g. IL-8 and CXC chemokine ligand (CXCL) 1,−2,−3,−5,
−6, and−16 genes) [126]. Increased expression of genes
encoding for negative regulators of the interferon response
has been also observed, including several members of the
SOCS gene family (e.g., SOCS2 and−3 genes) [127].
In this framework, our group evaluated differential
gene expression by microarray analysis on liver biop-
sies obtained from chronic HCV and control negative
patients [128]. Unique gene signatures were identified
and, in particular, the HCV infected liver tissue showed
strong up-regulation of genes involved in antigen presen-
tation, protein ubiquitination, interferon signaling, IL-4
signalling, bacteria and viruses cell cycle and chemokine
IL-4 signalling pathways.
Data analysis focused on the expression levels of specific
genes related to the innate immunity pathway showed a
strong up-regulation of genes involved, at multiple levels, in
the pathway of Type I IFN signalling, including the STAT1
transcription factor and the downstream regulated genes
(ISGs), in agreement to studies from other groups [129].
Among the observed up-regulated ISGs, gamma-
interferon-inducible protein 16 (IFI16), interferon alpha-
inducible protein 27 (IFI27) and 20-50-oligoadenylate
synthase-like (OASL) were identified. In particular, IFI16
controls cellular proliferation by modulating the functions
of cell cycle regulatory factors including p53/TP53 and theretinoblastoma protein (pRb) [130,131]. IFI27 is known to
promote cell death, triggering an IFN-induced apoptosis
with robust release of cytochrome C from the mitochon-
dria and activation of BCL2-associated X protein (BAX)
and caspases 2, 3, 6, 8 and 9 [132]. Furthermore, the 20-50-
oligoadenylate synthase-like protein (OASL) has been
shown to bind double-stranded RNA and DNA, suggest-
ing a role in anti-viral activity [133].
Moreover, MHC components of antigen processing and
presentation such as HLA-F, Beta-2-microglobulin (B2M),
CD7 and TAP1, have been found up-regulated in HCV-
positive liver tissue. In particular, TAP1 is involved in the
transport of antigens from the cytoplasm to the endoplas-
mic reticulum for association with MHC class I molecules
[134]. Indeed, it is well known that HCV core protein
enhances MHC class I molecule function, by increasing the
expression of TAP1, thus contributing to HCV persistence
by suppressing the cytotoxic activity of NK cells [135].
Furthermore, data analysis focused on the expression
levels of specific genes related to the innate immunity
pathway show a relevant activation trend of the flagellin-
dependent TLR5, associated with the activation of IRAK1
(variant 3) and decreased level of IL-10 and IL-1b (submit-
ted for publication).
Such overall data shed light on specific pathogenetic
mechanisms and gene signatures involved in HCV-related
disease and suggest the relevant role of innate immunity
in progression of HCV infection. Furthermore, the ana-
lysis of relevant pathways and specific genes involved in
HCV progression to cancer may have a relevant impact
on the early identification of “progressors” to select for
appropriate therapeutic actions.
Indeed, despite advances have been made in the treat-
ment of HCV chronic infection with the combination of
pegylated interferon (PEG-IFN) and ribavirin, treatment
failure still occurs in about half of the patients and pre-
diction of treatment response would be of great value.
In this perspective, several studies employed gene ex-
pression profiling analysis to investigate the molecular
basis for treatment failure in HCV chronic infection.
In particular, a systems biology approach using high-
throughput technologies, such as complementary DNA
microarrays combined with mathematical modeling, was
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tained virological response to PEG-IFN plus ribavirin in
patients with HCV chronic hepatitis [136,137].
To this aim, expression profiling analysis was performed
on liver biopsy specimens taken before therapy and gene
expression levels were compared among 15 nonrespon-
ders (NR), 16 responders (R), and 20 healthy subjects.
Eighteen genes were differentially expressed between
responders and nonresponders. Up-regulation of a specific
set of IFN-responsive genes predicted poor response to ther-
apy, suggesting a possible rationale for treatment resistance.
In particular, upregulation of the following 8 genes
showed the most consistent ability to classify NR and R
subjects: ISG15, activating transcription factor 5 (ATF5),
IFN-induced protein with tetratricopeptide repeats (IFIT1),
MX1, ubiquitin-specific protease 18 (USP18), dual specifi-
city phosphatase 1 (DUSP1), cyclin E binding protein
(CEB1) and 40S ribosomal protein S28 (RPS28). Overall,
the study showed that different innate IFN response to
HCV infection may significantly impact on the responsive-
ness to PEG-IFN plus ribavirin therapy and identify NR
and R patients [137].Conclusions
The host immune response plays a critical role in HCV in-
fection because of its potential to contribute not only to
viral clearance but also to liver injury. HCV attenuates both
innate and adaptive immune responses, thereby reducing
the viral clearance as well as the degree of immune-
mediated liver injury, allowing coexistence of both virus
and host. Key questions for future studies remain for nearly
every aspect of the host immune response; so far, the
pathogenetic mechanisms involved in progression to dis-
tinct HCV-related malignant tumors are still ill defined.
However, the analysis of the innate immune pathways
involved in HCV chronic infection would help elucidat-
ing the possible mechanisms leading to HCV related
cancers, such as HCC or B-cell NHL.
Future studies focused on the analysis of relevant
pathways and specific genes involved in HCV infection
and progression to cancer would have a relevant impact
on the understanding of HCV-related carcinogenesis
(HCC and/or B cell NHL) as well as on the management
of HCV-infected subjects, making easier the identifica-
tion of “progressors” to select for appropriate prevent-
ive/therapeutic actions.
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